Structural basis for chemical inhibition of human blood coagulation factor Xa.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  1998-06-09

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1073/PNAS.95.12.6630PMID 9618463PMCID PMC22577
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes.

  1997cited by this paper
• Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo.

  1997cited by this paper
• Molecular design and characterization of an alpha-thrombin inhibitor containing a novel P1 moiety.

  1997cited by this paper
• Activation-dependent Exposure of the Inter-EGF Sequence Leu83-Leu88 in Factor Xa Mediates Ligand Binding to Effector Cell Protease Receptor-1*

  1997cited by this paper
• Effector Cell Protease Receptor-1, a Platelet Activation-dependent Membrane Protein, Regulates Prothrombinase-catalyzed Thrombin Generation*

  1997cited by this paper
• Crystallographic determination of the structures of human alpha-thrombin complexed with BMS-186282 and BMS-189090.

  1996cited by this paper
• The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor

  1996cited by this paper
• Crystallographic determination of the structures of human α‐thrombin complexed with BMS‐186282 and BMS‐189090

  1996cited by this paper
• X-ray Structure of Active Site-inhibited Clotting Factor Xa

  1996cited by this paper
• Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human α‐thrombin

  1996cited by this paper
• Structure-based understanding of ligand affinity using human thrombin as a model system.

  1996cited by this paper
• Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design.

  1996cited by this paper
• DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.

  1996cited by this paper
• Crystal structures of thrombin with thiazole-containing inhibitors: probes of the S1' binding site.

  1996cited by this paper
• Effector Cell Protease Receptor-1 Is a Vascular Receptor for Coagulation Factor Xa*

  1996cited by this paper
• The 2.8 A crystal structure of Gla‐domainless activated protein C.

  1996cited by this paper
• The relative orientation of Gla and EGF domains in coagulation factor X is altered by Ca2+ binding to the first EGF domain. A combined NMR-small angle X-ray scattering study.

  1996cited by this paper
• Crystal structure of a peptidyl pyridinium methyl ketone inhibitor with thrombin.

  1995cited by this paper
• Synthetic low-molecular weight thrombin inhibitors: the ideal antithrombotic drug? An introduction.

  1995cited by this paper
• Proteases and protease receptors in modulation of leukocyte effector functions

  1995cited by this paper
• The X-ray crystal structure of thrombin in complex with N alpha-2-naphthylsulfonyl-L-3-amidino-phenylalanyl-4-methylpiperidide: the beneficial effect of filling out an empty cavity.

  1995cited by this paper
• X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B.

  1995cited by this paper
• Crystal structure of human alpha-thrombin complexed with hirugen and p-amidinophenylpyruvate at 1.6 A resolution.

  1995cited by this paper
• How an epidermal growth factor (EGF)-like domain binds calcium. High resolution NMR structure of the calcium form of the NH2-terminal EGF-like domain in coagulation factor X.

  1994cited by this paper
• Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors.

  1994cited by this paper
• The CCP4 suite: programs for protein crystallography.

  1994cited by this paper
• Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.

  1994cited by this paper
• DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa

  1994cited by this paper
• AMoRe: an automated package for molecular replacement

  1994cited by this paper
• Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa.

  1994cited by this paper
• The structure of a designed peptidomimetic inhibitor complex of α-thrombin

  1993cited by this paper
• Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile.

  1993cited by this paper
• The structure of a designed peptidomimetic inhibitor complex of alpha-thrombin.

  1993cited by this paper
• Structure of human des(1-45) factor Xa at 2.2 A resolution.

  1993cited by this paper
• Free R value: a novel statistical quantity for assessing the accuracy of crystal structures.

  1992cited by this paper
• Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.

  1992cited by this paper
• Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics.

  1992cited by this paper
• Three-dimensional structure of the apo form of the N-terminal EGF-like module of blood coagulation factor X as determined by NMR spectroscopy and simulated folding.

  1992cited by this paper
• Free R value: a novel statistical quantity for assessing the accuracy of crystal structures

  1992cited by this paper
• Sparse matrix sampling: a screening method for crystallization of proteins

  1991cited by this paper
• Improved methods for building protein models in electron density maps and the location of errors in these models.

  1991cited by this paper
• Anticoagulant activity of a peptide boronic acid thrombin inhibitor by various routes of administration in rats.

  1991cited by this paper
• The coagulation cascade: initiation, maintenance, and regulation.

  1991cited by this paper
• Inhibition by Recombinant Hirudins of Experimental Venous Thrombosis and Disseminated Intravascular Coagulation Induced by Tissue Factor in Rats

  1990cited by this paper
• Slow-cooling protocols for crystallographic refinement by simulated annealing.

  1990cited by this paper
• Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H.

  1990cited by this paper
• Crystallographic R Factor Refinement by Molecular Dynamics

  1987cited by this paper
• Preparation and properties of derivatives of bovine factor X and factor Xa from which the gamma-carboxyglutamic acid containing domain has been removed.

  1986cited by this paper
• Comparison of coagulation factor Xa and des-(1-44)factor Xa in the assembly of prothrombinase.

  1984cited by this paper

• Decoding ECM remodeling: proteases as gatekeepers of Lysyl oxidase family-mediated crosslinking.

  2026cites this paper
• Rivaroxaban to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease: a narrative review

  2025cites this paper
• Characterization of a novel factor X variant, p.F139L, associated with bleedings in heterozygous and compound heterozygous form.

  2025cites this paper
• Analyzing 6211 unique variants in the upgraded interactive FVIII web database reveals novel insights into hemophilia A

  2025cites this paper
• Serious issues with cryo-EM structures of human prothrombinase

  2025influential citation
• Edge Oxidation Redirects Coagulation Factor X Binding on Graphene Nanosheets: Insights from All-Atom Simulations.

  2025cites this paper
• Conformation of factor Xa in solution revealed by single molecule spectroscopy.

  2024cites this paper
• A roadmap to the enzymes from spider venom: biochemical ecology, molecular diversity, and value for the bioeconomy

  2024cites this paper
• The Prothrombin-Prothrombinase Interaction.

  2024cites this paper
• Membrane-bound model of the ternary complex between factor VIIa/tissue factor and factor X

  2024cites this paper
• Biocompatible reactions: advances in kinetic target-guided synthesis

  2023cites this paper
• Cryo-EM structure of coagulation factor V short

  2023cites this paper
• Structural properties of newly 4,7-dihydroxycoumarin derivatives as potential inhibitors of XIIa, Xa, IIa factors of coagulation

  2023cites this paper
• Cryo‐EM structures of coagulation factors

  2022cites this paper
• Parallel imaging of coagulation pathway proteases activated protein C, thrombin, and factor Xa in human plasma

  2022cites this paper
• Cryo-EM structure of the prothrombin-prothrombinase complex

  2022cites this paper
• Analysis of 180 Genetic Variants in a New Interactive FX Variant Database Reveals Novel Insights into FX Deficiency

  2021cites this paper
• Tissue factor-related mechanisms of coagulation initiated on the virus envelope

  2019cites this paper
• In vitro toxicity assessment of rivaroxaban degradation products and kinetic evaluation to decay process

  2019cites this paper
• MS methods to study macromolecule-ligand interaction: Applications in drug discovery.

  2018cites this paper
• Protein-Ligand Docking in Drug Design: Performance Assessment and Binding-Pose Selection.

  2018cites this paper
• Lipid specificity of the membrane binding domain of coagulation factor X

  2017cites this paper
• A review on the synthetic approaches of rivaroxaban: An anticoagulant drug

  2017cites this paper
• Proteintemplat-gesteuerte Bildung eines Inhibitors des Koagulationsfaktors Xa durch eine Amidierung ohne Hintergrundreaktion

  2017cites this paper
• Protein‐Templated Formation of an Inhibitor of the Blood Coagulation Factor Xa through a Background‐Free Amidation Reaction

  2017cites this paper
• Characterization of three main degradation products from novel oral anticoagulant rivaroxaban under stress conditions by UPLC-Q-TOF-MS/MS.

  2016cites this paper
• Discovery of Novel Nonactive Site Inhibitors of the Prothrombinase Enzyme Complex

  2016cites this paper
• FUNCTIONAL STUDIES WITH DIRECT ORAL ANTICOAGULANTS: INVESTIGATION OF THE REGULATION OF KEY BLOOD COAGULATION PROTEASES

  2016cites this paper
• A model for the unique role of factor Va A2 domain extension in the human ternary thrombin-generating complex.

  2015cites this paper
• Alginate/Poly(γ-glutamic Acid) Base Biocompatible Gel for Bone Tissue Engineering

  2015cites this paper
• Quantitative Correlation of Conformational Binding Enthalpy with Substrate Specificity of Serine Proteases

  2015cites this paper
• Ultra-performance LC-ESI/Q-TOF MS for the Rapid Analysis of Rivaroxaban: Method Validation Using Experimental Design for Robustness Evaluation

  2015cites this paper
• Homology model of human prothrombinase based on the crystal structure of Pseutarin C

  2014cites this paper
• MODELING, ADME SCREENING & QSAR STUDIES ON FACTOR-XA INHIBITORS

  2014cites this paper
• Ensemble-Based Docking Using Biased Molecular Dynamics

  2014cites this paper
• Structural glycobiology of heparin dynamics on the exosite 2 of coagulation cascade proteases: Implications for glycosaminoglycans antithrombotic activity.

  2014influential citation
• suggests new intermolecular binding sites hemophilia A patients: structural analysis of 20 missense mutations Identification of 31 novel mutations in the F8 gene in Spanish

  2013cites this paper
• Modeling of human factor Va inactivation by activated protein C

  2012cites this paper
• Oral Direct Factor Xa Inhibitors

  2012cites this paper
• The role of structural information in the discovery of direct thrombin and factor Xa inhibitors.

  2012cites this paper
• Protein Pharmacophore Selection Using Hydration-Site Analysis

  2012cites this paper
• Coagulation Factor Xa

  2012cites this paper
• Profiling the Structural Determinants for the Selectivity of Representative Factor-Xa and Thrombin Inhibitors Using Combined Ligand-Based and Structure-Based Approaches

  2011cites this paper
• Novel function of coagulation factor Xa : conversion into a clot-dissolving cofactor

  2011influential citation
• The action of Amblyomma cajennense tick saliva in compounds of the hemostatic system and cytotoxicity in tumor cell lines.

  2011cites this paper
• Developments in factor Xa inhibitors for the treatment of thromboembolic disorders

  2011cites this paper
• Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban

  2010cites this paper
• Synthesis of a versatile 2 (1H)-pyrazinone core for the preparation of Tissue Factor-Factor VIIa inhibitors

  2010cites this paper
• Structural Aspects of the Factor X Activator RVV-X from Russell’s Viper Venom

  2010cites this paper
• Skeletal Muscle-specific Calpain Is an Intracellular Na+-dependent Protease*

  2010cites this paper
• Functional and structural characterization of factor Xa dimer in solution.

  2009cites this paper
• Crystal structures of snake venom metalloproteinases and the molecular mechanism of factor X activation by Russell's viper venom

  2009cites this paper
• Swelling and biocompatibility of sodium alginate/poly(γ‐glutamic acid) hydrogels

  2009cites this paper
• Tick-derived Kunitz-type inhibitors as antihemostatic factors.

  2009cites this paper
• Identification of 31 novel mutations in the F8 gene in Spanish hemophilia A patients: structural analysis of 20 missense mutations suggests new intermolecular binding sites.

  2008cites this paper
• Role of the active-site solvent in the thermodynamics of factor Xa ligand binding.

  2008cites this paper
• Locus specific databases: integrating sequence, structural and clinical analysis in relation to disorders of the coagulation and complement systems.

  2008cites this paper
• A Molecular Model of the Human Prothrombinase Complex

  2008cites this paper
• Molecular dynamics simulations of Factor Xa: insight into conformational transition of its binding subsites.

  2008cites this paper
• CoagMDB: a database analysis of missense mutations within four conserved domains in five vitamin K–dependent coagulation serine proteases using a text‐mining tool

  2008cites this paper
• Computational study of the putative active form of protein Z (PZa): Sequence design and structural modeling

  2008influential citation
• Active and exo-site inhibition of human factor Xa: structure of des-Gla factor Xa inhibited by NAP5, a potent nematode anticoagulant protein from Ancylostoma caninum.

  2007cites this paper
• Design, Synthesis and Evaluation of Serine Protease Inhibitor Analogues

  2007cites this paper
• Intermolecular interactions and characterization of the novel factor Xa exosite involved in macromolecular recognition and inhibition: crystal structure of human Gla-domainless factor Xa complexed with the anticoagulant protein NAPc2 from the hematophagous nematode Ancylostoma caninum.

  2007cites this paper
• A proposed structural model of human protein Z

  2007cites this paper
• Crystal structure of RVV‐X: An example of evolutionary gain of specificity by ADAM proteinases

  2007cites this paper
• Characterization of Three Novel Mutations in the Sodium Binding Site of Coagulation Factor X

  2007cites this paper
• Factor X and Factor X Deficiency

  2007cites this paper
• Proposed structural models of the prothrombinase (FXa–FVa) complex

  2006cites this paper
• Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.

  2006cites this paper
• Approaches to Selective Peptidic Inhibitors of Factor Xa

  2006cites this paper
• Quantifizierung von Kation‐π‐Wechselwirkungen in Protein‐Ligand‐Komplexen: Kristallstrukturanalyse eines Komplexes von Faktor Xa und einem quartären Ammonium‐Ion‐Liganden

  2005cites this paper
• Pharmacophore Identification, in Silico Screening, and Virtual Library Design for Inhibitors of the Human Factor Xa

  2005cites this paper
• Homology modelling of transferrin-binding protein A from Neisseria meningitidis.

  2005cites this paper
• Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of Factor Xa bound to a quaternary ammonium ion ligand.

  2005cites this paper
• Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions.

  2005cites this paper
• Structures and functions of snake venom CLPs (C-type lectin-like proteins) with anticoagulant-, procoagulant-, and platelet-modulating activities.

  2005cites this paper
• Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element.

  2004cites this paper
• Design, synthesis, and evaluation of oxyanion-hole selective inhibitor substituents for the S1 subsite of factor Xa.

  2004cites this paper
• Role of the γ‐carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin–heparin

  2004cites this paper
• Two new factor X mutations (Pro382Leu and Phe356Cys) associated with low activity and low antigen levels

  2004cites this paper
• Understanding protein-ligand interactions: the price of protein flexibility.

  2004cites this paper
• Use of Snake Venom Inhibitors in Studies of the Function and Tertiary Structure of Coagulation Factors

  2004cites this paper
• Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).

  2004cites this paper
• Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors.

  2004cites this paper
• Virtual screening with flexible docking and COMBINE-based models. Application to a series of factor Xa inhibitors.

  2004cites this paper
• Design, synthesis and structure-activity relationships of benzoxazinone-based factor Xa inhibitors.

  2003cites this paper
• Conformation of a bound inhibitor of blood coagulant factor Xa.

  2003cites this paper
• The tissue factor/factor VIIa/factor Xa complex: A model built by docking and site‐directed mutagenesis

  2003cites this paper
• Exposure of platelet membrane phosphatidylserine regulates blood coagulation.

  2003cites this paper
• Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials.

  2003cites this paper
• Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket.

  2003cites this paper
• Computer-aided design of a factor Xa inhibitor by using MCSS functionality maps and a CAVEAT linker search.

  2003cites this paper
• The extended interactions and Gla domain of blood coagulation factor Xa.

  2003cites this paper
• ZZ made EZ: influence of inhibitor configuration on enzyme selectivity.

  2003cites this paper
• Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.

  2003cites this paper
• Human factor Xa bound amidine inhibitor conformation by double rotational-echo double resonance nuclear magnetic resonance and molecular dynamics simulations.

  2003cites this paper
• Determination of the P1', P2' and P3' subsite-specificity of factor Xa.

  2003cites this paper
• Reconstructing the binding site of factor Xa in trypsin reveals ligand-induced structural plasticity.

  2003cites this paper
• A New Method for Ligand-supported Homology Modelling of Protein Binding Sites: Development and Application to the neurokinin-1 receptor

  2003cites this paper